Takeda San Diego, Inc.

Agios Pharmaceuticals, Inc.

Takeda Pharmaceutical Company Limited

Takeda California, Inc.

Technoderma Medicines Pte Ltd.

Eubulus Biotherapeutics Inc.

Sheldon Cao

Jeffrey Alan Stafford

Zhixiong Ye

Phong H Vu

Jerome C Bressi

Janeta Popovici-Muller

Xiao-Yi Xiao

Stephen L Gwaltney

Anthony R Gangloff

Jun Feng

Jason W Brown

Giovanni Cianchetta

Andrew John Jennings

Yan Liu

Francesco Gerald Salituro

Robert Zahler

Jeffrey O Saunders

Stephen W Kaldor

Jeremy Mark Travins

Shunqi Yan

Xuefei Tan

Andre A Kiryanov

Mingnam Tang

Xiaolei Wang

Robert J Skene

David J Hosfield

Michael Brennan Wallace

Zhe Nie

Zhiyuan Zhang

Benjamin Jones

Rene Marc Lemieux

Betty Lam

Edcon Chang

Bheema Rao Paraselli

Beverly Lynn Wolgast

Prasuna Guntupalli

Yasuhisa Kohara

Takashi Ichikawa

Kathleen Aertgeerts

Chen Mao

Victoria Feher

Yue Ding

David J Hossfield

Chrisopher McBride

Hidehisa Iwata

Nancy K Brennan

Hasanthi P Wijesekera

Srinivasa Ready Natala

Zengquan Wang

Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a GPX4-mediated disorder, disease, or condition in a subject with a GPX4 inhibitor and an anticancer agent. Also provided herein are methods of inducing ferroptosis in a cell or inhibiting the growth of a cell with a GPX4 inhibitor and an anticancer agent.

GPX4 inhibitor in combination with anticancer agent for treating proliferative disease

Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer.

Compounds and their methods of use

Provided is a small molecule compound as represented by structural formula (I). The product of the present invention in various concentrations and dosages can achieve an obvious change in the growth period of hairs, promoting the growth of the hairs, thus exhibiting an obvious effect of promoting hair growth. In addition, changes in the weight of a mouse in each group are slow, indicating that the test compound does not cause weight loss in an animal.

Small molecule compound and synthesizing method and uses thereof

Provided are piperazine compounds of Formula I useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described here. 

Therapeutically active compositions and their methods of use

Provided are compounds of formula (I), wherein X, Y, Z, W, V, R, Rand m are defined as in the description. Their pharmaceutical compositions and their uses for treating cancers are also provided.

Phenyl and pyridinyl substituted piperidines and piperazines as inhibitors of IDH1 mutants and their use in treating cancer

Compounds of general formula I: and compositions comprising compounds of general formula I that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.

Therapeutic compounds and compositions

Compounds are provided which have the formula: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture which contain such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to activate glucokinase.

Substituted isoindoles as glucokinase activators

Compounds of the following formula are provided for use with kinases: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

Polo-like kinase inhibitors

Compounds, pharmaceutical compositions, kits and methods are provided for use with glucokinase that comprise a compound selected from the group consisting of formula (I) wherein the variables are as defined herein. 

Imidazopyridine compounds

Compounds are provided for use with hexokinases that comprise: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

Substituted indazoles as glucokinase activators

Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV inhibitors comprising Formula I: wherein the substituents are as described herein.

Dipeptidyl peptidase inhibitors

Compounds, pharmaceutical compositions, kits and methods are provided for use with hydroxysteroid dehydrogenases that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.

Hydroxysteroid dehydrogenase inhibitors

Compounds, pharmaceutical compositions, kits and methods are provided for use with kinases that comprise a compound of the formula: wherein R, R, R, Q, U, V, W, X, and Y are as defined herein.

Kinase inhibitors

Histone deacetylase inhibitors and uses thereof are provided that have the general formula wherein R, R, Rand Rare each independently selected from the group consisting of hydrogen, a substituted or unsubstituted straight chained Calkyl, Caminoalkyl or Coxaalkyl, and a substituted and unsubstituted 3, 4, 5, 6, 7 or 8 membered ring, with the proviso that Rand Rare not both hydrogen; Ris selected from the group consisting of a carbonyl, a substituted or unsubstituted Calkyl, a substituted or unsubstituted &#x2014;Calkyl-C(O), a substituted or unsubstituted &#x2014;C(O)&#x2014;Calkyl, and a substituted or unsubstituted &#x2014;C(O)C(O)Calkyl; M is a substituent capable of complexing with a protein metal ion; and L is a substituent comprising a chain of 3-12 atoms connecting the M substituent to the carbon atom alpha to the L substituent.

Histone deacetylase inhibitors

Growing community of inventors

San Diego, CA, United States of America

Sheldon Cao